Fresenius Medical Care's operating profit surges in Q4

Fresenius Medical Care reported a sharp rise in fourth‑quarter operating income on Tuesday, helped by accelerating cost savings and favourable reimbursement effects.

Reuters • 21 hours ago

Fresenius Medical Care AG (FMS) Q4 2025 Earnings Call Transcript

Fresenius Medical Care AG (FMS) Q4 2025 Earnings Call Transcript

Seeking Alpha • 7 hours ago

Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

Strong organic revenue growth1 in 2025 of 8% driven by all operating segments Driven by an exceptional Q4, full year operating income2 growth of 27% reached top end of financial outlook, resulting in a significant margin step up to 11.3% Reported operating income grew by 31%, reported net income3 by 82% Earnings per share2 (EPS) grew by 44%, supported by the accelerated share buyback program Dividend of EUR 1.49 (+3%) planned to be proposed FY 2026 outlook operating income is forecast to remain on a consistent level despite significant additional headwinds BAD HOMBURG, Germany, Feb. 24, 2026 /PRNewswire/ -- "Fresenius Medical Care closed a milestone year marked by outstanding profitability gains. Over the past three years, we built a stronger and more resilient company, meeting all key financial and strategic aspects of the mid-term outlook that we had set for 2025.

PRNewsWire • 15 hours ago

Fresenius Medical Care Shares Drop After Outlook, U.S. Performance Underwhelms

Shares in the dialysis specialist were down 7.1% in European midday trade, with the decline erasing gains since the start of 2026.

WSJ • 16 hours ago

Here's Why Fresenius (FMS) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Feb 9, 2026

FMS or MASI: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Instruments stocks have likely encountered both Fresenius (FMS) and Masimo (MASI). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Jan 26, 2026

Why Fresenius (FMS) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Jan 23, 2026

3 Undervalued Medical Instrument Stocks Poised to Grow in 2026

FMS, IART and STE trade below historical valuations. Easing cost pressure and improved execution set the stage for potential upside in 2026 for these companies.

Zacks Investment Research • Jan 16, 2026

Reasons to Add Fresenius Medical Stock to Your Portfolio Now

FMS' acquisitions, partnerships and global reach fuel growth, even as rising costs and optimization efforts weigh on near-term performance.

Zacks Investment Research • Jan 15, 2026

Fresenius Medical Care AG (FMS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Fresenius Medical Care AG (FMS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026